TB-500 for Wound Healing: What the Evidence Actually Shows

What Is TB-500 and Why Are Women Using It Off-Label?

TB-500 refers to a synthetic peptide that corresponds to the active fragment of thymosin beta-4 (Tβ4), a 43-amino-acid protein found in virtually every cell in the human body. The fragment most commonly sold as "TB-500" is the actin-binding sequence Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), though some suppliers offer a longer fragment. It is not the same compound as full-length thymosin beta-4, and the two should not be treated as interchangeable in terms of pharmacology or safety.

Women are turning to TB-500 through wellness clinics, compounding pharmacies, and online peptide vendors, primarily because of claims that it accelerates wound closure, reduces scar formation, and speeds recovery from soft-tissue injuries. Interest has grown sharply since 2020 in the functional medicine and biohacking communities, where it is often stacked with BPC-157 (another unapproved peptide). No professional women's health organization, including ACOG or The Menopause Society, has issued guidance on TB-500, which itself is a meaningful signal about where the evidence stands.

How TB-500 Is Supposed to Work

Thymosin beta-4 modulates actin polymerization, which is essential for cell migration during wound repair. In preclinical models, Tβ4 and its fragments have shown the ability to promote keratinocyte and endothelial cell migration, stimulate angiogenesis, and reduce inflammatory cytokine signaling. The Ac-SDKP fragment specifically has been studied for its role in inhibiting fibrosis, including cardiac and renal fibrosis in animal models.

The proposed mechanism is biologically plausible. Cells need to migrate across a wound bed to close it, and actin dynamics drive that migration. The issue is that "biologically plausible" and "clinically proven" are very different things, and the gap between them is where most peptide therapies currently sit.

The Off-Label and Regulatory Reality

TB-500 has no FDA-approved indication for any condition, in any population. It is not approved for wound healing, musculoskeletal injury, or any other use. The FDA has repeatedly warned that compounded peptides lacking approved drug status cannot legally be marketed for clinical use. This means that any TB-500 you receive from a compounding pharmacy or wellness clinic is being provided outside the standard regulatory framework that governs drug safety and efficacy.

This is not a minor footnote. It means no mandatory lot-release testing, no standardized purity requirements, and no post-market pharmacovigilance network tracking adverse events in women like you.

What the Evidence Actually Shows for Wound Healing

The evidence for TB-500 in wound healing is currently GRADE Very Low. That rating means the available data is so limited, or so indirect, that any estimate of effect could change substantially with one well-designed human trial.

Animal and In-Vitro Studies

The most frequently cited evidence comes from animal models. A series of studies in the early 2000s by Goldstein and colleagues showed that thymosin beta-4 accelerated full-thickness wound closure in mice by promoting keratinocyte migration and new blood vessel formation. A 2010 study in rats demonstrated that Tβ4 reduced inflammation and promoted healing in corneal wounds. These are genuinely interesting findings.

The problem is that mice are not women. Rodent skin heals through a contraction mechanism that differs substantially from the re-epithelialization process that dominates in human wound closure. Results from these models have a poor track record of translating directly to clinical benefit in people.

In-vitro work has confirmed that the Ac-SDKP fragment inhibits TGF-beta1-driven fibroblast activation, which is relevant to scar reduction. Again, cell culture is even further removed from the complex healing environment of a real wound in a living woman.

Human Data: Thin and Not Women-Specific

Human data on TB-500 specifically (as opposed to full-length thymosin beta-4) is sparse. A small phase I/II trial examined thymosin beta-4 (not the truncated fragment sold as TB-500) in patients with pressure ulcers and venous stasis ulcers, finding modest acceleration of wound closure compared to placebo. The trial enrolled 72 participants, was industry-funded, and was never followed by a confirmatory phase III study.

A separate pilot study in non-healing diabetic foot ulcers showed a trend toward faster closure with Tβ4 treatment, but the sample size was too small to draw firm conclusions, and the study was not powered to detect meaningful clinical endpoints.

To be direct: there is no completed phase III randomized controlled trial demonstrating that TB-500, or even full-length thymosin beta-4, significantly improves wound healing outcomes in humans. The two constructs are different molecules, and the data from full-length Tβ4 trials cannot be cleanly extrapolated to the synthetic fragment marketed as TB-500.

What Studies Are Missing

No published study has examined TB-500 specifically in women across different hormonal states, which matters clinically. Estrogen is a known modulator of wound healing. Postmenopausal women heal more slowly than age-matched men, and estrogen replacement has been shown to restore more youthful healing kinetics in some studies. Women with PCOS have elevated androgens and chronic low-grade inflammation that may alter how any anti-inflammatory peptide performs. No trial has looked at any of this.

Sex-Specific Physiology: Why Your Hormones Change the Picture

Your menstrual cycle, menopausal status, and any hormonal therapy you are taking are not incidental details. They are likely to influence how a pro-angiogenic, anti-inflammatory peptide like TB-500 behaves in your body, even if no trial has studied this directly.

Estrogen and Wound Repair

Estrogen has well-documented wound-healing effects. It upregulates TGF-beta1, increases collagen synthesis, and accelerates re-epithelialization. Women in the reproductive years who have normal estrogen levels may have a different baseline healing environment than postmenopausal women with low estrogen. If TB-500 works partly by amplifying the same pathways that estrogen activates, women on hormone therapy (HT) may see different outcomes than those who are not, but this is entirely speculative because no study has looked.

Perimenopause and Post-Menopause

During perimenopause and post-menopause, declining estrogen slows wound healing at the cellular level. Collagen content in skin drops roughly 30% in the first five years after menopause, and inflammatory resolution becomes less efficient. Some clinicians in the functional medicine space have proposed that this is precisely when a pro-healing peptide might offer the most benefit, but that hypothesis has not been tested in any clinical trial. What we know is that postmenopausal women are underrepresented in the small human Tβ4 trials that exist.

PCOS and Chronic Inflammation

Women with PCOS carry a background state of low-grade systemic inflammation, driven partly by hyperinsulinemia and androgen excess. Whether TB-500's proposed anti-inflammatory mechanism would interact with this differently than in metabolically healthy women is unknown. The PCOS-specific data does not exist.

The Menstrual Cycle Timing Question

Some functional medicine practitioners suggest timing peptide injections to specific cycle phases, theorizing that the follicular phase (higher estrogen) creates a more anabolic environment for tissue repair. There is no clinical trial data supporting this. It is pattern-matching from reproductive endocrinology applied to a context where the relevant studies have never been done.

Pregnancy, Lactation, and Contraception

TB-500 should not be used during pregnancy. This is not a soft caution. It is a hard stop based on the complete absence of human gestational safety data combined with the biological plausibility of fetal risk.

Pregnancy

Thymosin beta-4 is expressed endogenously during fetal development and plays a role in cardiac morphogenesis and vascular formation. Introducing supraphysiologic levels of a synthetic fragment that modulates the same actin-binding and angiogenic pathways during organogenesis is an untested intervention with theoretical teratogenic potential. No animal reproductive toxicology studies have been conducted on the specific Ac-SDKP fragment sold as TB-500. No human pregnancy registry exists. The FDA has not assigned a pregnancy category because the drug is not approved.

If you are pregnant, trying to conceive, or not using reliable contraception while using TB-500, you need to stop and speak with your clinician today.

Lactation

There are no lactation transfer studies for TB-500. Endogenous thymosin beta-4 is present in human breast milk, but the pharmacokinetics of an exogenously administered synthetic fragment differ from endogenous protein in ways that have not been characterized. Until transfer and infant exposure data exist, breastfeeding women should avoid TB-500.

Contraception Requirements

TB-500 is not a recognized teratogen in the formal sense (because it has never been adequately studied), but the absence of data is not the same as the absence of risk. Women of reproductive age who choose to use TB-500 despite the evidence limitations should use reliable contraception throughout any course of treatment.

Who This Might Be Considered For and Who Should Avoid It

This section is framed around life stage and current evidence, not a recommendation to use TB-500.

Potentially Lowest-Risk Group (With Significant Caveats)

Non-pregnant, non-breastfeeding women of reproductive age or postmenopausal women who are not immunocompromised, are not on concurrent hormonal therapies with unknown interactions, have discussed the off-label use with a physician who can monitor them, and have an informed understanding that the evidence base is at the animal-study level. Even in this group, "lowest risk" does not mean "low risk." It means least unknowns among a set of substantial unknowns.

Women Who Should Avoid TB-500

• Pregnant women or those trying to conceive
• Breastfeeding women
• Women with active or prior malignancy (Tβ4 has pro-angiogenic activity that is theoretically relevant to tumor vascularization)
• Women on immunosuppressive therapy
• Women with autoimmune conditions, given the absence of immune-interaction data
• Women who would be obtaining TB-500 from unverified online vendors where purity and identity cannot be confirmed

Dosing, Administration, and What Wellness Clinics Are Prescribing

Because TB-500 is off-label and unregulated, there is no established clinical dosing protocol. The figures circulating in wellness and biohacking communities are derived from the early-phase human Tβ4 trials and from animal study scaling, neither of which is a reliable guide for clinical dosing in women.

The doses most commonly cited include a "loading phase" of 2 to 2.5 mg injected subcutaneously or intramuscularly two to three times per week for four to six weeks, followed by a "maintenance phase" of 2 mg once every two to four weeks. These numbers appear to originate from the Goldstein-era wound-healing trials and have been repeated in wellness literature without critical appraisal.

Body weight-based dosing has been proposed by some compounding clinics, but no pharmacokinetic study in women has established what dose produces what plasma concentration, how cycle phase or menopausal status affects distribution, or what the therapeutic window (if one exists) looks like. Absorption from subcutaneous versus intramuscular routes has also not been formally characterized for this fragment in women.

The purity and identity of commercially available TB-500 preparations vary significantly. A 2018 analysis of research peptides sold online found that a substantial proportion of products did not match label claims for identity or concentration. This is not a small quality-control problem. It means that the dose you inject may not correspond to what the label states.

How TB-500 Compares to Approved Wound-Healing Interventions

Women seeking faster healing after surgical procedures, cesarean sections, postpartum perineal tears, or dermatologic interventions have access to evidence-based options that TB-500 does not yet rival.

Becaplermin (Regranex)

Becaplermin is the only topical growth factor FDA-approved for chronic diabetic neuropathic ulcers. It contains recombinant human platelet-derived growth factor (PDGF-BB) and has completed phase III trials. The evidence quality far exceeds anything available for TB-500.

Negative Pressure Wound Therapy

For complex wounds, including those following obstetric surgery or abdominal procedures, negative pressure wound therapy (NPWT) has a substantial evidence base in both accelerating closure and reducing infection rates. NPWT is covered by most insurers for qualifying wounds; TB-500 is not covered by any insurer because it is not approved.

Collagen-Based Dressings

Multiple randomized trials support the use of collagen matrix dressings in chronic wound management. These are inexpensive, widely available, and backed by Cochrane-level evidence.

The point is not that TB-500 is certainly inferior. The point is that we do not know where it sits relative to these options because no head-to-head trial has been done.

Monitoring and What to Watch For

If you are using TB-500 under clinician supervision, there are no validated biomarkers or monitoring protocols because none have been studied. Some clinicians order basic metabolic panels, CBC, and inflammatory markers (CRP, ESR) at baseline and periodically during treatment, on the rationale that these provide a general safety net. This is reasonable practice in the absence of specific guidance, not an evidence-based monitoring protocol.

Reported side effects in the small human trials and in case series from wellness clinics include injection-site pain and erythema, mild fatigue in the first one to two weeks, and transient headache. These are self-reported and have not been systematically tracked. No serious adverse events have been reported in the published pilot literature, but the total number of humans studied is small enough that rare events would not yet be detectable.

Women on hormonal contraceptives, HT, or thyroid medication should inform their prescribing clinician before starting TB-500, given the complete absence of drug-interaction data.

The Evidence Gap Is a Women's Health Issue

Women have been historically underrepresented in clinical drug trials, and the peptide therapy space reflects this problem in an especially acute way. The small human Tβ4 studies that exist enrolled mixed-sex populations without stratifying by hormonal status, cycle phase, or reproductive life stage. When the sample sizes are in the dozens, female-specific subgroup analysis is impossible.

As WomanRx's reviewer Dr. Elena Vasquez notes: "The near-total absence of women-specific data on TB-500 is not a gap we should accept as normal. A woman's hormonal environment is not a confounding variable to be controlled away. It is a core part of her physiology, and any peptide claiming to accelerate healing needs to be tested within it, not around it."

This gap matters practically. If estrogen modulates the same actin-cytoskeletal pathways that TB-500 targets, then a trial that does not stratify by menopausal status may be reporting an average effect that does not describe any real subgroup well. The evidence gap is not just an academic problem. It is the reason a definitive recommendation cannot be made for or against TB-500 in any specific group of women.